Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127563581 | 12756358 | 1 | I | 20130907 | 20160905 | 20160916 | 20160916 | EXP | ZA-GILEAD-2016-0232434 | GILEAD | 73.00 | YR | E | M | Y | 74.90000 | KG | 20160916 | MD | ZA | ZA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127563581 | 12756358 | 1 | PS | EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1 DF, QD | D | 21937 | 1 | DF | TABLET | QD | |||||
| 127563581 | 12756358 | 2 | SS | EFAVIRENZ | EFAVIRENZ | 1 | Oral | 600 MG, QD | 0 | 600 | MG | QD | |||||||
| 127563581 | 12756358 | 3 | SS | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 12.5 MG, QD | D | 0 | 12.5 | MG | QD | ||||||
| 127563581 | 12756358 | 4 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD | |||||||
| 127563581 | 12756358 | 5 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | 0 | ||||||||||||
| 127563581 | 12756358 | 6 | SS | ENALAPRIL MALEATE. | ENALAPRIL MALEATE | 1 | Oral | 10 MG, UNK | D | 0 | 10 | MG | |||||||
| 127563581 | 12756358 | 7 | SS | ENALAPRIL MALEATE. | ENALAPRIL MALEATE | 1 | D | 0 | |||||||||||
| 127563581 | 12756358 | 8 | SS | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 25 MG, UNK | 0 | 25 | MG | QD | ||||||||
| 127563581 | 12756358 | 9 | SS | ABACAVIR. | ABACAVIR | 1 | Oral | 300 MG, QD | 0 | 300 | MG | QD | |||||||
| 127563581 | 12756358 | 10 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Oral | 150 MG, BID | 0 | 150 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127563581 | 12756358 | 1 | Retroviral infection |
| 127563581 | 12756358 | 2 | Retroviral infection |
| 127563581 | 12756358 | 3 | Hypertension |
| 127563581 | 12756358 | 4 | Hypertension |
| 127563581 | 12756358 | 5 | Cardiac failure congestive |
| 127563581 | 12756358 | 6 | Hypertension |
| 127563581 | 12756358 | 7 | Cardiac failure congestive |
| 127563581 | 12756358 | 8 | Cardiac failure congestive |
| 127563581 | 12756358 | 9 | Retroviral infection |
| 127563581 | 12756358 | 10 | Retroviral infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127563581 | 12756358 | OT |
| 127563581 | 12756358 | HO |
| 127563581 | 12756358 | DE |
| 127563581 | 12756358 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127563581 | 12756358 | Cardiac failure congestive |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127563581 | 12756358 | 1 | 20130715 | 20130823 | 0 | |
| 127563581 | 12756358 | 2 | 20130823 | 0 | ||
| 127563581 | 12756358 | 3 | 20130615 | 0 | ||
| 127563581 | 12756358 | 4 | 20130615 | 0 | ||
| 127563581 | 12756358 | 6 | 20130715 | 20130823 | 0 | |
| 127563581 | 12756358 | 8 | 20130729 | 0 | ||
| 127563581 | 12756358 | 9 | 20130823 | 0 | ||
| 127563581 | 12756358 | 10 | 20130823 | 0 |